FDC Share Price

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages,among others. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries FDC share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Several factors influence the FDC stock price, including quarterlyearnings, regulatory approvals, new product launches, and shifts in healthcare spending patterns. In the longer term, strategies such as expansion into new therapeutic areas, deepening international presence, and leveraging its strong brand equity in ORS and ophthalmics significantly impact stock market sentiment. All these factors must be closely monitored to have an idea about the FDC price movements.

FDC live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of FDC live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the FDC share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identifypossible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

FDC LIMITED COMPANY FUNDAMENTALS

a. Company Background

FDC Limited is an Indian multinational pharmaceutical and consumer healthcare company. The company was incorporated on 22 December 1936 and its registered office is located at 3rd Floor, Trade World, B Wing, Kamala Mills Compound, Lower Parel, Mumbai, Maharashtra, India. FDC is best known for pioneering the Oral Rehydration Salts (ORS) market in India with its iconic brand, Electral, and has since built a strong presence in ophthalmics, anti-infectives, and other therapeutic segments. The company operates in a competitive pharmaceutical landscape and focuses on research, quality manufacturing, and expanding its global footprint. Guided by a mission to provide quality and affordable healthcare, FDC aims to strengthen its position in both domestic and international markets.

b. Company Products

• Oral Rehydration Salts (ORS):

• • Electral (multiple flavours and pack sizes)

• • Enerzal (Electrolyte Powder & Drink)

• Anti-infectives:

• • Zifi (Cefixime)

• • Zoxan (Ciprofloxacin)

• • Zocon (Fluconazole)

• • Zathrin (Azithromycin)

• • Vitcofol (Haematinics)

• Ophthalmics:

• • Iotim (Timolol)

• • Ocudor (Dorzolamide)

• • Iobrim (Brimonidine)

• • Latanoprost

• • Allercrom (Sodium Cromoglicate)

• Cardiovascular:

• • Amodep AT (Amlodipine & Atenolol)

• Gastrointestinal:

• • Simyl MCT (Infant Formula & Fat Supplement)

• Other Therapeutic Areas:

• • Otek AC Neo (Otological Drops)

• • Corticosteroids, Anti-coagulants, Analgesic-Antipyretics

• • Creams, Dusting Powders, Syrups, and Injections

c. Company Revenue Model

• Revenue is primarily generated through the sale of pharmaceutical formulations and consumer healthcare products.

• Strong dependence on flagship brands like Electral and Zifi for consistent income, leveraging decades of brand equity.

• Domestic sales network contributes a significant share via a wide network of stockists, sub-stockists, and retailers across India.

• Products are sold through retail pharmacies, hospitals, government tenders, and e-commerce platforms.

• Export revenues form a growing component, driven by institutional and distribution partnerships in over 50 countries.

• Focus on a brand-driven pricing strategy, capitalising on strong brand recall and quality perception.

• Expansion into value-added products and new therapeutic areas to improve margins.

• Strategic investments in marketing and direct-to-consumer initiatives to sustain brand visibility.

• Use of manufacturing and supply chain efficiencies to control costs and improve profitability.

• Increasing emphasis on digital channels and online pharmacy platforms.

• Partnerships with international distributors to scale overseas revenue and enter new markets.

• Innovation-led launches aimed at capturing new consumer and patient segments.

d. Geographic Presence

• Strong presence across India, with deep penetration in urban and semi-urban markets.

• Extensive distribution network covering over 1 lakh retail outlets nationwide.

• Products available in more than 50 countries globally, with a strong presence in:

• Africa: Kenya, Nigeria, South Africa, Tanzania, Uganda, Zambia, Zimbabwe, and others.

• Asia-Pacific: Malaysia, Philippines, Vietnam, Sri Lanka, Thailand, Hong Kong.

• Middle East: UAE, Oman.

• Europe: UK, Germany, Spain, Netherlands, Ukraine, Moldova.

• Americas: Chile, Colombia, Peru, Curacao, Dominican Republic.

• Oceania: Australia, New Zealand.

• Region-specific product customisation and registrations based on local regulatory requirements.

• Dedicated international business teams managing regional growth and market access.

e. Leadership

Some of the key leaders of FDC Limited as of April 2026 are:

• Ashok R. Shetty – Chairman & Non-Executive Director

• Nomita A. Shetty – Managing Director

• Ramdas Athawale – Independent Director

• S. Krishnamurthy – Independent Director

• M. S. Kulkarni – Independent Director

• Shashank Shetty – Executive Director & Chief Financial Officer

• Laxman Shetty – Executive Director

• R. A. Shetty – Executive Director

• Aruna S. Shetty – Non-Executive Director

• Prakash M. Jha – Company Secretary & Compliance Officer

f. Key Milestones

• 1936: Incorporation of Fairdeal Corporation (later FDC Limited).

• 1950s-60s: Introduction of pioneering formulations in ophthalmics.

• 1976: Launch of Electral, India’s first ORS, establishing a new market category.

• 1990s: Expansion into anti-infectives and other therapeutic segments.

• 2000s: Strengthening of international business and portfolio diversification.

• 2010-2020: Continued focus on ophthalmics and consumer healthcare; Zifi becomes a leading brand.

• 2020-2024: Growth in ORS and hygiene products during the pandemic; expansion of manufacturing capacity.

• 2025-2026: Continued focus on global expansion, particularly in regulated markets, and strengthening of digital and innovation capabilities.

g. Industry Perspective

FDC Limited operates in the pharmaceutical industry, a critical global healthcare sector focused on drug development, manufacturing, and distribution. Globally, the pharmaceutical market exceeds USD 1.5 trillion and is expected to grow at ~5–7% CAGR, driven by ageing populations, chronic diseases, and innovation in biologics and specialty drugs. India, however, is among the fastest-growing markets and a global supply hub. The Indian pharmaceutical market was valued at ~USD 68.4 billion in 2025 and is projected to reach ~USD 174.7 billion by 2034, growing at ~10.98% CAGR . Other estimates suggest growth from ~USD 66.7 billion in 2025 to ~USD 88.9 billion by 2030 (~5.9% CAGR), indicating steady expansion across segments . India contributes ~20% of global generic drug supply and 55–60% of UNICEF vaccine demand, reinforcing its “pharmacy of the world” status . The sector has over 3,000 companies and ~10,500 manufacturing units, with exports reaching ~USD 30.47 billion in FY25 (+9.4% YoY) . Future growth will be driven by biologics, biosimilars (growing ~22% CAGR), contract manufacturing, and policy support, with long-term industry growth expected to sustain ~10–12% CAGR, making India a key global pharma innovation and manufacturing hub.

FDC Stock Market Presence: Listings & Index Representation

FDC Limited was listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) following its incorporation and subsequent growth. The company’s stock is actively traded on these exchanges, with the BSE scrip code being 531599 and the NSE symbol being FDC.

The company has a notable presence in key stock market indices, reflecting its standing in the pharmaceutical sector. FDC is included in indices such as the S&P BSE Healthcare, BSE 1000, S&P BSE 250 SmallCap Index, S&P BSE 400 MidSmallCap Index, Nifty Microcap 250 Index, Nifty Total Market, S&P BSE MidSmallCap, S&P BSE SmallCap, S&P BSE AllCap, and S&P BSE 500. Its presence in these indices, particularly the healthcare and small-cap indices, highlights its relevance to investors tracking the pharmaceuticals and healthcare space.

FDC stock price is regularly tracked by both retail and institutional investors. Its inclusion in these major indices underscores its market capitalization and its role within the pharmaceuticals sector. Listing on the NSE and BSE ensures high liquidity, while its presence in sectoral and broad-market indices allows for benchmark comparisons and passive fund flows.

FDC Stock Performance and FDC Share Price History

FDC share price on NSE and BSE reflects its position as a significant entity within the pharmaceutical sector. The company’s stock performance is driven by factors like sales volume growth, raw material prices, R&D investments, and regulatory approvals. Investors often compare the FDC share price today with the Nifty Pharma index and other pharmaceutical peers to assess its relative performance.

These fundamental drivers are often visible in the stock’s movement during different market phases. For example, a strong quarterly performance with margin expansion typically leads to positive price action. Similarly, sector-wide trends, such as a focus on domestic pharma, have supported the FDC share price in the past. Corporate actions, including buybacks or dividend announcements, can also impact the FDC share price in the short term, even when the company’s long-term business fundamentals remain stable. Such events highlight how corporate decisions can create short-term price movements.

While short-term moves are driven by events and quarterly results, the long-term valuation context is better captured by the FDC share price 52-week high and low. The 52-week high of ₹527.80, recorded in the past year, reflects periods of strong investor confidence. The 52-week low of ₹312.95 indicates periods of market correction, sector-wide slowdowns, or company-specific challenges. These levels provide essential context for the stock’s historical performance.

The historical performance of FDC stock price illustrates the trading patterns of a pharmaceutical company navigating evolving market dynamics. The FDC stock price has experienced periods of significant growth, often linked to strong brand equity and export market expansion. Over the past year, the FDC share price has shown a decline of 16.66%. In contrast, the 3-year return stands at 28.09%, showcasing a period of long-term value creation, while the 10-year return is 77.27%, indicating robust growth over the longer horizon.

The FDC stock price performance is closely tied to domestic healthcare policies and export market dynamics. For instance, the FDC share price reached an all-time high of ₹658.85 in the past, reflecting peak market optimism. The FDC stock price has seen significant gains in the 5-year period with a return of 14.83%, driven by operational improvements and favourable market conditions. However, recent quarters have been challenging, with a 3-month return of -22.41% and a 6-month return of -25.77%, highlighting the FDC stock price’s sensitivity to both company-specific actions and broader economic trends.

Despite facing challenges such as volatile input costs and shifting regulatory landscapes, the FDC share price has shown resilience over the long term. The FDC stock price performance over the last three years, with a 28.09% return, outpacing the Sensex’s 23.97%, suggests a period of relative strength. During periods of market-wide volatility, the company’s established brand presence and consistent dividend payouts have provided a degree of stability, helping the FDC share price retain investor interest even when the broader pharmaceutical sector faced headwinds.

FDC Investor Relevance and Role in Portfolio

FDC is considered a representative play within the small-cap pharmaceutical space, offering exposure to India’s branded generics and consumer healthcare consumption story. Its inclusion in the S&P BSE SmallCap and Healthcare indices underscores its relevance for investors tracking healthcare and small-cap segments. The company’s established brand portfolio and extensive distribution network make it a consideration for portfolios focused on domestic consumption and healthcare.

A broad mix of institutional investors holds equity in FDC, reflecting its prominence in the pharmaceutical sector. Key institutional stakeholders include Leo Advisors Private Limited, ICICI Prudential Asset Management Company Limited, Nippon Life India Asset Management Limited, Dimensional Fund Advisors LP, Tata Asset Management Pvt. Ltd, Investor Education and Protection Fund (IEPF), State Street Global Advisors, Inc., BlackRock, Inc., Bandhan AMC Limited, and Motilal Oswal Asset Management Company Limited.

Prominent mutual fund holders include Nippon Mutual Funds – Nippon India Small Cap Fund, ICICI Prudential Mutual Fund – ICICI Prudential Smallcap Fund, ICICI Prudential Mutual Fund – ICICI Prudential Pharma Healthcare And Diagnostics Fund, ICICI Prudential AMC Ltd. – ICICI Prudential Mutual Fund – ICICI Prudential ESG Fund, Tata Mutual Fund – Tata India Pharma & Healthcare Fund, ICICI Prudential Mutual Fund – ICICI Prudential MNC Fund, Bandhan Mutual Fund – Bandhan Small Cap Fund, SPDR Index Shares Funds – State Street SPDR Portfolio Emerging Markets ETF, DFA Investment Dimensions Group Inc. – Emerging Markets Core Equity 2 Portfolio, and ICICI Prudential Mutual Fund – ICICI Prudential Bharat Consumption Fund.

The FDC share price is also tracked through technical indicators, which can provide insight into short-term momentum shifts. Tools like RSI, MACD, and MFI are sometimes used by market participants to gauge sentiment and potential volatility around key events like quarterly earnings or product launches. While primarily used for short-term trading, these indicators can help portfolio managers understand market positioning.

The beta of FDC provides a measure of its volatility relative to the market. The long-term beta for the stock is 1.05, indicating it is generally slightly more volatile than the broader market. The beta varies across different time frames, offering insight into its short-term correlation. The daily beta for a one-month range is 0.236, while for a three-month range it is 0.362, suggesting lower correlation with daily market movements in the near term. Over a weekly period, the one-year beta is 0.627, and the two-year beta is 0.908, showing a higher correlation over longer weekly periods. The 2-week, two-year beta is 1.01, and the monthly, two-year beta is 1.32. This data shows that while FDC stock price can experience varying levels of correlation with the market, its long-term price movements have shown a slight tendency to be more volatile than the market.

FDC Sectoral Relevance and Peer Positioning

FDC’s sector relevance stems from its strong foothold in the ORS and ophthalmics categories, brand recognition, and extensive domestic and international distribution. It competes with other pharmaceutical and consumer healthcare companies like Cipla Limited, Sun Pharmaceutical Industries Limited, Lupin Limited, GlaxoSmithKline Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, and Alkem Laboratories Limited. Peer comparisons often focus on market share in key categories, brand strength, distribution efficiency, and margin profiles. These benchmarks help in assessing the company’s operational scale and its ability to navigate input cost pressures and competitive intensity within India’s pharmaceutical market.

FDC’s market cap has shown a fluctuating trend over the last ten years, reflecting its business cycles and market sentiment. As of March 2025, the market cap stood at ₹52.28 billion. This represents a 1-year change of -15.0% from ₹61.51 billion in March 2024. The market cap in March 2024 had increased by 26.6% from ₹48.57 billion in March 2023. The year 2023 saw a growth of 19.8% from ₹40.55 billion in 2022. The market cap in 2022 was ₹40.55 billion, a 27.4% increase from ₹31.84 billion in 2021. Over a 10-year period, the market cap has grown from ₹21.58 billion in March 2015 to ₹52.28 billion in March 2025, achieving a 10-year CAGR of approximately 9.2%, demonstrating long-term value creation despite year-on-year fluctuations.

FDC’s earnings history shows a period of growth followed by recent volatility. In FY2015, net profit was ₹145.9 Cr, which grew to a peak of ₹307.2 Cr in FY2024. The profit then declined by 10.9% to ₹273.6 Cr in FY2025. Over the past five years, net profit grew from ₹219.6 Cr in FY2021 to ₹273.6 Cr in FY2025, a 5-year CAGR of 4.5%. However, the 3-year CAGR stands at 7.6%, while the 10-year CAGR is a robust 6.5%. The TTM net profit as of December 2025 is ₹227.1 Cr, which is a decline from the annual peak, indicating near-term pressure. The profit margins have also seen variation, with the Net Profit Margin (NPM) moving from 16.6% in FY2015 to 13.2% in FY2025, reflecting changing cost dynamics and competitive pressures.

FDC EPS has mirrored the net profit trend, showing growth and subsequent moderation. In March 2015, the adjusted EPS was ₹9.0. It grew steadily to ₹18.9 in March 2024, representing a significant increase. However, the EPS for March 2025 declined to ₹16.8, a year-on-year drop of 11.1%. The TTM EPS as of December 2025 is ₹14.0, indicating further contraction. The 5-year CAGR for EPS is 2.0%, while the 10-year CAGR is a stronger 6.5%. The quarterly EPS has been volatile, with a high of ₹7.5 in June 2025 and a low of ₹1.7 in December 2025, highlighting the impact of quarterly performance on this metric. This pattern reflects the challenges in maintaining consistent earnings per share growth in the competitive pharmaceutical sector.

FDC P/E ratio provides insight into how the market values its earnings stream. In March 2025, the P/E stood at 20.0, a decrease from 26.6 in March 2024, which had been a significant increase from 16.7 in March 2023. The P/E in March 2023 was 16.7, up from 13.5 in March 2022, which was a decrease from 19.5 in March 2021. Over the last five years, the P/E has shown wide fluctuations, from a high of 30.8 in 2020 to a low of 13.5 in 2022. These changes reflect shifts in investor sentiment, earnings growth expectations, and the broader market’s valuation of the pharmaceutical sector. The current P/E of around 20 suggests a valuation that is sensitive to the near-term earnings decline, while the historical averages indicate a more stable long-term valuation range.

Summary

FDC operates in India’s pharmaceutical and consumer healthcare sector with a focus on branded formulations, ORS, and ophthalmics. Its stock is listed on the NSE and BSE and is part of several small-cap and healthcare indices. The company’s market performance is tied to brand strength, distribution, and regulatory developments. Its institutional ownership includes a mix of domestic and global funds. The FDC share price has shown varied performance, with significant long-term returns but recent declines reflecting cyclical pressures and company-specific dynamics.